Dextrose
Dextrose 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Shift Work Schedule、Circadian Rhythm、Insulin Resistance、Circadian Misalignment。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
1 项
已进入 III/IV 期
12 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Washington State University
- POLYSAN Scientific & Technological Pharmaceutical Company
- Op-T LLC
- University of Turin, Italy
- Tufts Medical Center
- Valbiotis
- Sheba Medical Center
- University of Texas Southwestern Medical Center
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
Russia、美国、意大利、加拿大、Israel、瑞士、中国、法国、比利时、Poland、德国、荷兰
正在招募患者的 Dextrose 研究
Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome
不适用招募中RussiaNCT06735898Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
II 期招募中美国NCT06964087Urea for Treatment of Hyponatremia in Patients With SIAD Unresponsive to Fluid Restriction
不适用招募中意大利NCT07528365Glucose Empowerment Through Monitoring and Social Support in Pregnancy
不适用招募中美国NCT07009704Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
不适用招募中加拿大NCT06704321Feasibility and Effectiveness of Tele-diabetes Remote System on Glycemic Control and Quality of Life of Children and Youth With Type 1 Diabetes
不适用招募中IsraelNCT07828106Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy
不适用招募中美国NCT06814587Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control
不适用招募中美国NCT06890676Cerebrovascular Disease: Quality of Life (CODE: QoL)
不适用招募中瑞士NCT06443268A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
I 期招募中美国NCT07842640Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
不适用招募中美国NCT07599982SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
II 期招募中中国NCT07482020Digital Solutions for Predicting the Biological Mechanisms of Alzheimer's Disease Through the Analysis of Risk Factors
不适用招募中意大利NCT07731191External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia
不适用招募中美国NCT07082478New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.
不适用招募中法国NCT06048510Phenotyping Genetic Risk for Type 2 Diabetes
不适用招募中美国NCT04024631The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
不适用招募中中国NCT06459141Continuous Glucose Monitoring (CGM) in an Underserved Population
不适用招募中美国NCT07135531Glucose Homeostasis, Metabolomics and Pregnancy Outcomes After Bariatric Surgery
不适用招募中比利时NCT05084339Comparison of 40% Glucose Solution and Autologous Blood Patch Pleurodesis for Postoperative Air Leak After Lung Resections
不适用招募中PolandNCT06936969Efficacy and Safety of SP16 in Preventing Acute Kidney Injury in At-risk Subjects With Chronic Kidney Disease Undergoing Elective Cardiac Surgery Using the Heart-lung-machine
II 期招募中德国NCT07661940Forearm Immobilization in T2D
不适用招募中荷兰NCT06750497Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus
II 期招募中美国NCT06729996Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
III 期招募中中国NCT07083154
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。